Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows
06:08am, Wednesday, 12'th May 2021
Although they have been struggling recently, these stocks remain attractive buys over the long term.
Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript
08:29am, Saturday, 01'st May 2021
Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
10:31am, Friday, 30'th Apr 2021
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Recap: Seagen Q1 Earnings
05:06pm, Thursday, 29'th Apr 2021
Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to ($0.67), which missed
Seattle Genetics's Earnings Outlook
10:55am, Wednesday, 28'th Apr 2021
Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings announcement.
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
01:33pm, Thursday, 22'nd Apr 2021
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
11:17am, Tuesday, 20'th Apr 2021
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 202
TOKYO and BOTHELL, Wash., April 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
09:51am, Monday, 12'th Apr 2021
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Seagen: The New Oncology Hope
04:09am, Monday, 12'th Apr 2021
In recent years, Seagen has undergone a transformation from a one-product company to a diversified player in the oncology drug market. The current conservative stock price based on the DCF model is $
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
06:10am, Wednesday, 07'th Apr 2021
Horizon Therapeutics has a clear path to significant sales growth.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
10:36am, Monday, 29'th Mar 2021
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
02:00am, Friday, 26'th Mar 2021
TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing autho
Moving Average Crossover Alert: Seagen
07:11am, Monday, 15'th Mar 2021
Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound?
12:08pm, Saturday, 13'th Mar 2021
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
